Related Experiment Video
Updated: Jan 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Familial hypomagnesaemia with secondary hypocalcaemia: novel TRPM6 variant
Rita Alvelos1,2, João Nico2,3, Marta Machado2
1Paediatric Service, Local Health Unit of the Aveiro Region, Aveiro, Portugal ritalvelos@gmail.com.
Abstract:
Familial hypomagnesaemia with secondary hypocalcaemia (HSH) is an autosomal recessive disease caused by mutations in the Transient Receptor Potential Melastatin 6 (TRPM6) gene. It manifests with severe hypomagnesaemia and hypocalcaemia, and its most common clinical presentation is seizures in early infancy. This is a case of an infant with HSH who presented with seizures. Investigation disclosed hypocalcaemia and hypomagnesaemia with undetectable calcitonin and normal parathyroid, and thyroid hormones and vitamin D. Only after a second admission was she discharged on long-term oral magnesium (Mg) supplementation. Genetic investigation revealed a novel variant in the TRPM6 gene. At the last consultation, the patient remained asymptomatic, without any complications, under Mg supplementation. Different homozygous mutations have been described in HSH. However, this case describes the presence of two heterozygous variants: c.5785del p.(Glu1929LysfsTer3), and c.3179T>A p.(Ile1060Asn). HSH might be responsible for permanent neurological sequelae. Nevertheless, the prognosis is good if diagnosis and treatment are established early.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Skeleton and Calcium Homeostasis

